Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02375971 · ClinicalTrials.gov registry record · Phase 3
RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 224
- Enrollment target
NCT02375971 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 224 participants.
The verdict
NCT02375971, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 224 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).
Interventions
- DRUG Ranibizumab
- PROCEDURE Laser therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02375971
The ClinicalTrials.gov registry entry for NCT02375971 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ranibizumab is the first listed.
NCT02375971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02375971 about?
NCT02375971 is a clinical study titled "RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity". The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).
What is the current status of trial NCT02375971?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2015-12-30. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT02375971?
The interventions under investigation include: Ranibizumab (DRUG), Laser therapy (PROCEDURE).
Who is sponsoring clinical trial NCT02375971?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.